🌸 Breast Cancer — 2026-W39

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Narrative review in Ann Oncol addressing evidence gaps in adjuvant therapy for premenopausal HR+/HER2- early breast cancer, covering ovarian suppression, genomic assay use, extended endocrine therapy, and survivorship issues. Offers a practical framework to individualize adjuvant treatment decisions in this distinct population.

Single-arm phase 2 trial in HER2-negative metastatic breast cancer treated with eribulin, published in Breast Cancer Research and Treatment. Confirms eribulin's efficacy and shows circulating tumor cell clearance correlates with progression-free survival, offering a potential on-treatment monitoring tool.

Phase 1 dose-expansion study of first-line E7389-LF chemotherapy in metastatic HER2-negative breast cancer, published in Breast Cancer Research. Shows a meaningful objective response rate and PFS in an unmet first-line population, supporting further development of this agent.

Exploratory subgroup analysis of the MINDACT phase III trial evaluating the 70-gene MammaPrint signature in clinically high-risk, genomically low-risk HR+/HER2- early breast cancer, published in Eur J Cancer. Reinforces that adjuvant chemotherapy adds little benefit even in higher clinical-risk subgroups when genomic risk is low, supporting continued use of the assay for chemotherapy de-escalation decisions.